These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2481856)

  • 1. Prostaglandin oligomeric derivatives inhibit in vitro formation of dehydrated cells from sickle red cells.
    Ohnishi ST; Katsuoka M
    Prostaglandins Leukot Essent Fatty Acids; 1989 Sep; 37(3):197-201. PubMed ID: 2481856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single cell laser light scattering spectroscopy in a flow cell: repeated sickling of sickle red blood cells.
    Peetermans JA; Nishio I; Ohnishi ST; Tanaka T
    Biochim Biophys Acta; 1987 Dec; 931(3):320-5. PubMed ID: 3676348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sickle cell disease: advances in the 1970s and challenge in the 1980s.
    Bunn HF
    Am J Pediatr Hematol Oncol; 1982; 4(2):166-71. PubMed ID: 6180652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitrendipine, nifedipine and verapamil inhibit the in vitro formation of irreversibly sickled cells.
    Ohnishi ST; Horiuchi KY; Horiuchi K; Jurman ME; Sadanaga KK
    Pharmacology; 1986; 32(5):248-56. PubMed ID: 2940606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of piracetam on sickle erythrocytes and sickle hemoglobin.
    Asakura T; Ohnishi ST; Adachi K; Ozguc M; Hashimoto K; Devlin MT; Schwartz E
    Biochim Biophys Acta; 1981 May; 668(3):397-405. PubMed ID: 7236716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro exposure to hydroxyurea reduces sickle red blood cell deformability.
    Huang Z; Louderback JG; King SB; Ballas SK; Kim-Shapiro DB
    Am J Hematol; 2001 Jul; 67(3):151-6. PubMed ID: 11391710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modification of sickle hemoglobin by acetaldehyde and its effect on oxygenation, gelation and sickling.
    Abraham EC; Stallings M; Abraham A; Garbutt GJ
    Biochim Biophys Acta; 1982 Jul; 705(1):76-81. PubMed ID: 7115734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sickle cells modified by an osmotic pulse in the presence of inositol hexaphosphate have decreased intracellular hemoglobin concentration and decreased in vitro sickling without prolonged in vivo survival.
    Franco R; Barker-Gear R; Silberstein E; Mayfield G; Weiner M; Palascak J; Green R
    Adv Exp Med Biol; 1992; 326():325-31. PubMed ID: 1295319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of erythrocyte sickling in vitro by DL-glyceraldehyde.
    Nigen AM; Manning JM
    Proc Natl Acad Sci U S A; 1977 Jan; 74(1):367-71. PubMed ID: 264689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the in vitro formation of irreversibly sickled cells by cepharanthine.
    Ohnishi ST
    Br J Haematol; 1983 Dec; 55(4):665-71. PubMed ID: 6671086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of glyceraldehyde on the structural and functional properties of sickle erythrocytes.
    Nigen AM; Manning JM
    J Clin Invest; 1978 Jan; 61(1):11-9. PubMed ID: 618907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of the in vitro formation of dense cells and of irreversibly sickled cells by charybdotoxin, a specific inhibitor of calcium-activated potassium efflux.
    Ohnishi ST; Katagi H; Katagi C
    Biochim Biophys Acta; 1989 Feb; 1010(2):199-203. PubMed ID: 2463852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Membrane-bound hemoglobin in the erythrocytes of sickle cell anemia.
    Sears DA; Luthra MG
    J Lab Clin Med; 1983 Nov; 102(5):694-8. PubMed ID: 6631167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dimethyl adipimidate: a new antisickling agent.
    Lubin BH; Pena V; Mentzer WC; Bymun E; Bradley TB; Packer L
    Proc Natl Acad Sci U S A; 1975 Jan; 72(1):43-6. PubMed ID: 1054514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modification of the acid elution technique for quantitation of fetal hemoglobin in individual erythrocytes.
    Bernstein SC; Bowman JE; Swift HH
    Hemoglobin; 1977; 1(4):313-31. PubMed ID: 70422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deoxyhemoglobin S: solubility vs. erythrocyte sickling.
    Vedvick TS; Koenig HM; Itano HA
    Clin Biochem; 1975 Aug; 8(4):288-90. PubMed ID: 1157297
    [No Abstract]   [Full Text] [Related]  

  • 17. Physiologic and rheologic effects of the antisickling agent ethacrynic acid and its N-butylated derivative on normal and sickle erythrocytes.
    Orringer EP; Blythe DS; Whitney JA; Brockenbrough S; Abraham DJ
    Am J Hematol; 1992 Jan; 39(1):39-44. PubMed ID: 1536139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostaglandin E2-hemoglobin AA and SS erythrocyte interaction (prostaglandin-erythrocyte interaction).
    Sobota JT; Gruber CA; Gilbertson TJ; Wilson J
    Am J Hematol; 1977; 2(2):133-43. PubMed ID: 18932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease.
    Oksenberg D; Dufu K; Patel MP; Chuang C; Li Z; Xu Q; Silva-Garcia A; Zhou C; Hutchaleelaha A; Patskovska L; Patskovsky Y; Almo SC; Sinha U; Metcalf BW; Archer DR
    Br J Haematol; 2016 Oct; 175(1):141-53. PubMed ID: 27378309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythrocyte composition in sickle-cell anemia.
    Hellerstein S; Bunthrarungroj T
    J Lab Clin Med; 1974 Apr; 83(4):611-24. PubMed ID: 4817782
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.